Abstracts tagged "osteoporosis"

Abstract Number: 0101 • ACR Convergence 2020
Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass
Michael R McClung¹, Michael A Bolognese², Jacques P Brown³, Jean-Yves Reginster⁴, Bente Langdahl⁵, Norma Ruiz-Santiago⁶, Yifei Shi⁶, Maria Rojeski⁶, Jen Timoshanko⁷, Cesar Libanati⁷, Helina Kassahun⁶ and Mary Oates⁶, ¹Oregon Osteoporosis Center, Portland, OR, ²Bethesda Health Research Center, Bethesda, MD, ³Laval University and CHU de Québec (CHUL) Research Centre, Québec City, Canada, ⁴University of Liège, Liège, Belgium, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab, an anti-sclerostin antibody that increases bone formation while decreasing bone resorption, reduces fracture risk within 12 months. Here we evaluate the effects of…
Abstract Number: 0119 • ACR Convergence 2020
Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
Donna Jose¹, Micah Yu², Karina Torralba³, Christina Downey⁴, Justin Dunn⁵ and Vinicius Cabido⁵, ¹Loma Linda University Medical Center, Ontario, CA, ²Loma Linda University Medical Center, Loma Linda, CA, ³Loma Linda University School of Medicine, Redlands, CA, ⁴Loma Linda University Medical Center, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda
Background/Purpose: Osteoporosis causes significant morbidity, mortality and healthcare burden. There continues to be a care gap in osteoporosis recognition, treatment and prevention. Several healthcare systems…
Abstract Number: 0544 • ACR Convergence 2020
Risk Factors for Lumbar Vertebral Osteoporosis Do Not Reflect Factors Traditionally Associated with Osteoporosis at the Hip
Marwan Bukhari¹ and Mrinalini Dey², ¹Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom
Background/Purpose: The most common site of osteoporotic fragility fractures is the thoracic spine. However, bone mineral density (BMD) measurements at the hip are used to…
Abstract Number: 1977 • ACR Convergence 2020
Delivering Fracture Prevention Through Telemedicine: A Process Evaluation
Karla Miller¹, Melissa Steffen², Aaron Seaman², Zachary Anderson¹, Janiel Green¹, Shardool Patel¹, Shylo Wardyn² and Samantha Solimeo², ¹Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ²Iowa VA Healthcare System, Iowa City, IA
Background/Purpose: Guidelines recommend osteoporosis screening using dual-energy X-ray absorptiometry (DXA) in men and women at risk for osteoporosis, but screening remains low, especially in men…
Abstract Number: 0102 • ACR Convergence 2020
Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study
Diana Camelia Dan¹, Youssef Ibrahimy², Berengere Aubry-Rozier³ and Daniel Aeberli⁴, ¹Lausanne University Hospital, Lausanne, Switzerland, ²University of Lausanne, Lausanne, Switzerland, ³Hôpital orthopédique, Lausanne, Switzerland, ⁴University Hospital of Bern, Bern, Switzerland
Background/Purpose: There is much controversy surrounding the loss of bone mass in patients with psoriasis arthritis (PsA). We wanted to evaluate the prevalence of osteoporosis…
Abstract Number: 0120 • ACR Convergence 2020
Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
Giovanni Adami¹, Angelo Fassio², Alessandro Giollo², Luca Idolazzi², Ombretta Viapiana¹, Davide Gatti² and Maurizio Rossini², ¹University of Verona, Verona, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy
Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
Abstract Number: 0650 • ACR Convergence 2020
Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout
Marco Ferrández-Jiménez¹, Irene Calabuig², Maria Luisa Peral², Miguel Gómez-Garberí¹ and Mariano Andrés², ¹Universidad Miguel Hernández de Elche, Alicante, Spain, ²Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain
Background/Purpose: Osteoporosis causes significant morbidity and mortality through the development of fragility fractures, including vertebral fractures (VF). Patients with gout may show an increased risk…
Abstract Number: 0103 • ACR Convergence 2020
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
Rachel Elam¹, Sandeepkumar Gupta², Omar Tolaymat², Sowmya Vasan³, Carolyn Crandall⁴, Jean Wactawski-Wende⁵, Karen Johnson⁶ and Laura Carbone², ¹Augusta University, Evans, GA, ²Augusta University, Augusta, GA, ³WHI, Seattle, WA, ⁴UCLA, Los Angeles, CA, ⁵University of Buffalo, Buffalo, NY, ⁶University of Tennessee Health Sciences Center, Memphis, TN
Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of…
Abstract Number: 0121 • ACR Convergence 2020
Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women
Rashmi Dhital¹, P. Daniel Nicholas², Gregory Emkey³ and Anthony Donato², ¹Reading Hospital and Medical Center, West Reading, ²Reading Hospital and Medical Center, West Reading, PA, ³Reading Hospital and Medical Center, Reading, PA
Background/Purpose: Total joint replacement (TJR) is the standard surgical treatment for end-stage hip and knee osteoarthritis (OA). Patient optimization may limit the need for early…
Abstract Number: 0926 • ACR Convergence 2020
Risk Factors for Fractures and Osteoporosis Among Patients with Systemic Sclerosis in a United States Cohort
Sina Famenini¹, Jamie Perin², Kristin Wipfler³, Kaleb Michaud⁴ and Zsuzsanna McMahan⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²JHUSPH, Baltimore, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Johns Hopkins University, Baltimore
Background/Purpose:Systemic sclerosis (SSc) is associated with several risk factors for osteoporosis and fractures due to malabsorption or malnutrition, physical disability, chronic inflammation, and use of…
Abstract Number: 0104 • ACR Convergence 2020
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Attila Hamar¹, Anita Pusztai², Edit Végh¹, Ágnes Horváth¹, Katalin Gulyás¹, Szilvia Szamosi¹, Zsófia Pethő¹, Nóra Bodnár¹, Boglárka Soós¹, Monika Czókolyová¹, Sándor Szántó¹, Gabriella Szűcs¹, Harjit Bhattoa¹, Gábor Nagy¹, Gábor Tajti¹, Andrea Domján¹, Katalin Hodosi¹ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary
Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…
Abstract Number: 0122 • ACR Convergence 2020
Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry
Nitasha Khullar¹, Lang Chen², Jeffrey R Curtis³, Joshua Baker⁴, Huifeng Yun³, Andreas Reimold⁵ and Maria (Maio) Danila⁶, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ⁶University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Many effective medications are available for osteoporosis treatment. However how rheumatologists use these therapies is not well understood, particularly in patients with concomitant rheumatologic…
Abstract Number: 0966 • ACR Convergence 2020
Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3
Zheni Stavre¹, JungMin Kim², Jae-Hyuck Shim² and Ellen Gravallese³, ¹University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to local and systemic bone loss. TNF is a key mediator of bone loss,…
Abstract Number: 0105 • ACR Convergence 2020
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Balázs Juhász¹, Katalin Gulyás¹, Ágnes Horváth¹, Edit Végh¹, Anita Pusztai², Ágnes Szentpétery³, Zsófia Pethő¹, Nóra Bodnár¹, Attila Hamar¹, Levente Bodoki¹, Harjit Bhattoa¹, Éva Szekanecz¹, Katalin Hodosi¹, Andrea Domján¹, Szilvia Szamosi¹, Csaba Horváth⁴, Sándor Szántó¹, Gabriella Szűcs¹, Hennie Raterman⁵, Oliver FitzGerald⁶ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ³Uppsala University Hospital, Uppsala, Sweden, ⁴Semmelweis University, Budapest, Hungary, ⁵Northwest Clinics, Alkmaar, Netherlands, ⁶Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…
Abstract Number: 0123 • ACR Convergence 2020
Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention
Matthew White¹ and Luke Barre², ¹Roger Williams Medical Center, Providence, RI, ²Hawthorn Medical Associates, Dartmouth, MA
Background/Purpose: Aromatase inhibitors (AI) are frequently used in hormone receptor-positive breast cancer, which encompasses nearly 75% of all breast cancers. By preventing peripheral estrogen production,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].